🇺🇸 FDA
Patent

US 11649261

Crystalline forms of a CD73 inhibitor and uses thereof

granted A61KA61K31/706A61K45/06

Quick answer

US patent 11649261 (Crystalline forms of a CD73 inhibitor and uses thereof) held by Arcus Biosciences, Inc. expires Mon May 11 2043 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Arcus Biosciences, Inc.
Grant date
Tue May 16 2023 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon May 11 2043 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
23
CPC classes
A61K, A61K31/706, A61K45/06, A61P, A61P35/00